Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.
Non Small Cell Lung Cancer|Lung Cancer|Nsclc|NSCLC Stage II|NSCLC, Stage III
RADIATION: Radiation Therapy|DRUG: Durvalumab
2-year PFS rate, Demonstrate an improvement in 2-year PFS rate compared to historical results., 2 years
The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.